270596-42-4

Basic information

• Product Name: BOC-(S)-3-AMINO-4-(4-CHLORO-PHENYL)-BUTYRIC ACID
• Synonyms: N-BETA-T-BUTOXYCARBONYL-L-BETA-HOMO(4-CHLOROPHENYL)ALANINE;N-T-BUTOXYCARBONYL-(S)-3-AMINO-4-(4-CHLOROPHENYL)BUTANOIC ACID;(S)-3-(BOC-AMINO)-4-(4-CHLOROPHENYL)BUTYRIC ACID;(S)-BOC-4-CHLORO-BETA-HOMOPHE-OH;RARECHEM AK PT B071;(L)-3-BOC-AMINO-4-(4-CHLORO-PHENYL)-BUTYRIC ACID;BOC-4-CHLORO-L-BETA-HOMOPHENYLALANINE;BOC-BETA-HOPHE(4-CL)-OH
• CAS NO: 270596-42-4
• Molecular Formula: C₁₅H₂₀ClNO₄
• Molecular Weight: 313.78
• Product Categories: 3-Amino-4-phenylbutyric Acid Analogs;3-Amino-4-phenylbutanoic Acid Analogs;B-Amino
• Mol File: 270596-42-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 470 °C at 760 mmHg
• Flash Point: 238 °C
• Appearance: /
• Density: 1.22 g/cm³
• Vapor Pressure: 1.23E-09mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.40±0.10(Predicted)
• CAS DataBase Reference: BOC-(S)-3-AMINO-4-(4-CHLORO-PHENYL)-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-(S)-3-AMINO-4-(4-CHLORO-PHENYL)-BUTYRIC ACID(270596-42-4)
• EPA Substance Registry System: BOC-(S)-3-AMINO-4-(4-CHLORO-PHENYL)-BUTYRIC ACID(270596-42-4)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• F: 10
• HazardClass: IRRITANT
• Hazardous Substances Data: 270596-42-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C15H20ClNO4/c1-15(2,3)21-14(20)17-12(9-13(18)19)8-10-4-6-11(16)7-5-10/h4-7,12H,8-9H2,1-3H3,(H,17,20)(H,18,19)/t12-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 270596-41-3 (S)-3-amino-4-(4-chlorophenyl)butanoic acid 
• 1878-66-6 4-chlorophenylacetic Acid 
• 1035695-08-9 5-[2-(4-chlorophenyl)-1-hydroxyethylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 51301-86-1 Boc-p-chloro-L-Phe-OH 
• 14173-39-8 p-chlorophenylalanine 

Downstream Products

• 756878-34-9 C₂₈H₃₆ClN₃O₅S 
• 406952-64-5 [1-(4-chloro-benzyl)-3-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-3-oxo-propyl]-carbamic acid tert-butyl ester 
• 1105710-29-9 (S)-tert-butyl 1-(4-chlorophenyl)-4-hydroxybutan-2-ylcarbamate 

Relevant articles and documents

SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS

Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

Chiral synthesis method for chiral beta-amino acid and synthesis method for medicinal intermediate

The invention relates to a chiral synthesis method for chiral beta-amino acid. The chiral synthesis method comprises the following steps: reacting a compound shown in formula (II) with an acylation reagent to prepare anhydride intermediate reaction liquid under the action of alkali; adding Meldrum's acid into the anhydride intermediate reaction liquid, and performing reaction to generate a compound shown in formula (III); reacting the compound shown in formula (III) with a compound shown in formula (IV) to generate a compound shown in formula (V); reducing the compound shown in formula (V) to generate a compound shown in formula (VI); performing acidic hydrolysis on the compound shown in formula (VI) to generate a compound shown in formula (I), i.e., the chiral beta-amino acid. The chiral synthesis method has the advantages of convenience for synthesis, low cost and simple process, and compared with a disclosed preparation method, is more suitable for industrial production.

UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.